Description

Simple

A medication used to treat congestion and a runny nose.

Clinical

An alpha and beta adrenergic agonist used to treat nasal and sinus congestion, as well as allergic rhinitis.

Overview

An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.

Pharmacology

Indication

For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism.

Pharmacodynamic

Pseudoephedrine is a sympathomimetic agent, structurally similar to ephedrine, used to relieve nasal and sinus congestion and reduce air-travel-related otalgia in adults. The salts pseudoephedrine hydrochloride and pseudoephedrine sulfate are found in many over-the-counter preparations either as sin... Read more

Mechanism of action

Pseudoephedrine acts directly on both alpha- and, to a lesser degree, beta-adrenergic receptors. Through direct action on alpha-adrenergic receptors in the mucosa of the respiratory tract, pseudoephedrine produces vasoconstriction. Pseudoephedrine relaxes bronchial smooth muscle by stimulating beta2... Read more

Absorption

Pseudoephedrine is readily and almost completely absorbed from the GI tract and there is no evidence of first-pass metabolism.

Protein binding

Pseudoephedrine does not bind to human plasma proteins over the concentration range of 50 to 2000 ng/mL

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

9-16 hours

Route of elimination

Information currently not available.

Toxicity

Common adverse reactions include nervousness, restlessness, and insomnia. Rare adverse reactions include difficult/painful urination, dizziness/lightheadedness, heart palpitations, headache, increased sweating, nausea/vomiting, trembling, troubled breathing, unusual paleness, and weakness.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Urinary Retention
      • Drugbank Id: DBCOND0001412
  • Regions: US
  • Patient Conditions:
      • Name: Severe Hypertension
      • Drugbank Id: DBCOND0058109
      • Modification Of:
        • Base:
          • Name: Hypertension
          • Drugbank Id: DBCOND0020037
        • Severity:
          • Includes:
            • severe
  • Regions: US
  • Patient Conditions:
      • Name: Severe Coronary Artery Disease
      • Drugbank Id: DBCOND0037446
      • Modification Of:
        • Base:
          • Name: Coronary Artery Disease
          • Drugbank Id: DBCOND0000554
        • Severity:
          • Includes:
            • severe
  • Regions: US
  • With Categories Coadmin:
      • Name: Monoamine Oxidase Inhibitors
      • Drugbank Id: DBCAT001004
      • Mesh Id: D008996
  • Regions: US
  • Patient Conditions:
      • Name: Narrow-angle glaucoma
      • Drugbank Id: DBCOND0095646

Food Interactions

  • Take without regard to meals.

Interactions

Type in a drug name to check for interaction with Pseudoephedrine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid
The risk or severity of hypertension can be increased when Pseudoephedrine is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazole
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Pseudoephedrine.
2,4-thiazolidinedione
The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Pseudoephedrine.
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3-isobutyl-1-methyl-7H-xanthine.
3,5-diiodothyropropionic acid
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3,5-diiodothyropropionic acid.
3,5-Diiodotyrosine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3,5-Diiodotyrosine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
The risk or severity of hypertension can be increased when Pseudoephedrine is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 6-O-benzylguanine.
7-Deazaguanine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 7-Deazaguanine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Pseudoephedrine.
7,9-Dimethylguanine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 7,9-Dimethylguanine.
8-azaguanine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 8-azaguanine.
8-chlorotheophylline
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 8-chlorotheophylline.
9-Deazaguanine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 9-Deazaguanine.
9-Methylguanine
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 9-Methylguanine.
Abaloparatide
The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Abaloparatide.